Clinical Trials Logo

Health-Care-Associated Pneumonia clinical trials

View clinical trials related to Health-Care-Associated Pneumonia.

Filter by:
  • None
  • Page 1

NCT ID: NCT01734694 Terminated - Bacteremia Clinical Trials

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

STOP-NT
Start date: October 2011
Phase: Phase 4
Study type: Interventional

For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.

NCT ID: NCT00543608 Terminated - Clinical trials for Ventilator-Associated Pneumonia

Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the clinical cure rates of two dosing regimens of iclaprim with vancomycin (every 12 hours [q12h]) in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.